<VariationArchive VariationID="655222" VariationName="NC_000014.9:g.(?_66879919)_(66880053_?)del" VariationType="Deletion" Accession="VCV000655222" Version="5" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-17" DateCreated="2019-08-14" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="652560" VariationID="655222">
      <GeneList>
        <Gene Symbol="GPHN" FullName="gephyrin" GeneID="10243" HGNC_ID="HGNC:15465" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>14q23.3-24.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="14" Accession="NC_000014.9" start="66508147" stop="67735355" display_start="66508147" display_stop="67735355" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="14" Accession="NC_000014.8" start="66974124" stop="67648524" display_start="66974124" display_stop="67648524" Strand="+" />
          </Location>
          <OMIM>603930</OMIM>
          <Haploinsufficiency last_evaluated="2024-06-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GPHN">Little evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2024-06-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GPHN">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NC_000014.9:g.(?_66879919)_(66880053_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>14q23.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="14" Accession="NC_000014.9" innerStart="66879919" innerStop="66880053" display_start="66879919" display_stop="66880053" variantLength="135" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="14" Accession="NC_000014.8" innerStart="67346637" innerStop="67346771" display_start="67346637" display_stop="67346771" variantLength="135" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000014.9" sequenceAccession="NC_000014" sequenceVersion="9" change="g.(?_66879919)_(66880053_?)del" Assembly="GRCh38">
            <Expression>NC_000014.9:g.(?_66879919)_(66880053_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000014.8" sequenceAccession="NC_000014" sequenceVersion="8" change="g.(?_67346637)_(67346771_?)del" Assembly="GRCh37">
            <Expression>NC_000014.8:g.(?_67346637)_(67346771_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000014.9:g.(?_66879919)_(66880053_?)del AND Sulfite oxidase deficiency due to molybdenum cofactor deficiency type C" Accession="RCV000811351" Version="5">
        <ClassifiedConditionList TraitSetID="1651">
          <ClassifiedCondition DB="MedGen" ID="C1854990">Sulfite oxidase deficiency due to molybdenum cofactor deficiency type C</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-07-25" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-07-25" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2019-08-14" MostRecentSubmission="2024-06-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">11095995</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23184456</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23393157</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24561070</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26613940</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1651" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="9040" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Molybdenum cofactor deficiency C</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Molybdenum cofactor deficiency, complementation group C</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Sulfite oxidase deficiency due to molybdenum cofactor deficiency type C</ElementValue>
                <XRef ID="MONDO:0014212" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">MOCODC</ElementValue>
                <XRef Type="MIM" ID="615501" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Molybdenum cofactor deficiency (MoCD) represents a spectrum, with some individuals experiencing significant signs and symptoms in the neonatal period and early infancy (termed early-onset or severe MoCD) and others developing signs and symptoms in childhood or adulthood (termed late-onset or mild MoCD). Individuals with early-onset MoCD typically present in the first days of life with severe encephalopathy, including refractory seizures, opisthotonos, axial and appendicular hypotonia, feeding difficulties, and apnea. Head imaging may demonstrate loss of gray and white matter differentiation, gyral swelling, sulci injury (typically assessed by evaluating the depth of focal lesional injury within the sulci), diffusely elevated T2-weighted signal, and panlobar diffusion restriction throughout the forebrain and midbrain with relative sparring of the brain stem. Prognosis for early-onset MoCD is poor, with about 75% succumbing in infancy to secondary complications of their neurologic disability (i.e., pneumonia). Late-onset MoCD is typically characterized by milder symptoms, such as acute neurologic decompensation in the setting of infection. Episodes vary in nature but commonly consist of altered mental status, dystonia, choreoathetosis, ataxia, nystagmus, and fluctuating hypotonia and hypertonia. These features may improve after resolution of the inciting infection or progress in a gradual or stochastic manner over the lifetime. Brain imaging may be normal or may demonstrate T2-weighted hyperintense or cystic lesions in the globus pallidus, thinning of the corpus callosum, and cerebellar atrophy.</Attribute>
                <XRef ID="NBK575630" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17388" />
                <XRef ID="17388" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">34870926</ID>
                <ID Source="BookShelf">NBK575630</ID>
              </Citation>
              <XRef ID="308400" DB="Orphanet" />
              <XRef ID="833" DB="Orphanet" />
              <XRef ID="C1854990" DB="MedGen" />
              <XRef ID="MONDO:0014212" DB="MONDO" />
              <XRef Type="MIM" ID="615501" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1845728" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-09" DateCreated="2019-08-14">
        <ClinVarSubmissionID localKey="NM_020806.4_14_Deletion (exon 5)|MedGen:C1854990" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000951612" DateUpdated="2024-06-09" DateCreated="2019-08-14" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-07-25">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">11095995</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23184456</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23393157</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24561070</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26613940</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with GPHN-related conditions. This variant is a gross deletion of the genomic region encompassing exon(s) 5 of the GPHN gene. This deletion is out-of-frame, and is expected to create a premature termination codon and result in an absent or disrupted protein product. Loss-of-function variants in GPHN are known to be pathogenic (PMID: 11095995, 23184456, 23393157, 24561070, 26613940).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GPHN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000014.8:g.(?_67346637)_(67346771_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1854990" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14505679</SubmissionName>
          <SubmissionName>SUB5371970</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1845728" TraitType="Disease" MappingType="XRef" MappingValue="C1854990" MappingRef="MedGen">
        <MedGen CUI="C1854990" Name="Sulfite oxidase deficiency due to molybdenum cofactor deficiency type C" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>